Proposed INN: List 104 <strong>WHO</strong> <strong>Drug</strong> <strong>Information</strong>, <strong>Vol</strong>. <strong>24</strong>, <strong>No</strong>. 4, <strong>2010</strong>solithromycinumsolithromycinsolithromycinesolitromicina(3aR,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-aminophenyl)-1H-1,2,3-triazol-1-yl]butyl}-4-ethyl-7-fluoro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-{[trideoxy-(dimethylamino)-β-D-hexopyranosyl]oxy}octahydro-2H-oxacyclotetradecino[4,3-b][1,3]oxazole-2,6,8,14(1H,7H,9H)-tetraoneantibiotic(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-aminophényl)-1H-1,2,3-triazol-1-yl]butyl}-4-éthyl-7-fluoro-11-méthoxy-3a,7,9,11,13,15-hexaméthyl-10-{[3,4,6-tridéoxy-3-(diméthylamino)-β-D-xylo-hexopyranosyl]oxy}octahydro-2H-oxacyclotétradécino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tétroneantibiotique(3aR,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-aminofenil)-1H-1,2,3-triazol-1-il]butil}-4-etil-7-fluoro-3a,7,9,11,13,15-hexametil-11-metoxi-10-{[tridesoxi-(dimetilamino)-β-D-hexopiranosil]oxi}octahidro-2H-oxaciclotetradecino[4,3-b][1,3]oxazol-2,6,8,14(1H,7H,9H)-tetraonaantibióticoC 43 H 65 FN 6 O 10 760981-83-7H 2 NNH 3 CNNH 3 CH 3 COO H 3 COH 3 C N OHCH 3HOOH CH 3HCHH3ONHO OCH 3 HCH 3OF CH 3talimogenum laherparepvecum #talimogene laherparepvectalimogène laherparépvectalimogén laherparepvecrecombinant replicating Herpes simplex type -1 virus vector, withICP47 and both copies of ICP34.5 genes deleted, expressing humangranulocyte macrophage colony stimulating factor (hGM-CSF) in theICP34.5 locigene therapy product (antineoplastic)vecteur viral Herpes simplex type 1 répliquant avec délétion du gèneICP47 et des deux copies du gène ICP34.5, exprimant le facteurhumain de développement des polynucléaires et des macrophages(hGM-CSF) dans les loci ICP34.5produit de thérapie génique (antinéoplasique)vector virus del Herpes simplex tipo-1 replicante recombinante condelección del gen ICP47 y las dos copias del gen ICP34.5, queexpresa el factor humano estimulante de colonias de granulocitos ymacrógafos (hGM-CSF) in los loci ICP34.5producto para terapia génica (antineoplásico)1187560-31-1394
<strong>WHO</strong> <strong>Drug</strong> <strong>Information</strong>, <strong>Vol</strong>. <strong>24</strong>, <strong>No</strong>. 4, <strong>2010</strong> Proposed INN: List 104telotristatumtelotristattélotristattelotristat4-(2-amino-6-{(1R -1-[4-chloro-2-(3-methyl-1H-pyrazol-1-yl) phenyl])-2,2,2-trifluoroethoxy}pyrimidin-4-yl)-L-phenylalaninetryptophan hydroxylase inhibitor4-(2-amino-6-{(1R)-1-[4-chloro-2-(3-méthyl-1H-pyrazol-1-yl)phényl]-2,2,2-trifluoroéthoxy}pryrimidin-4-yl)-L-phénylalanineinhibiteur de l'hydroxylase du tryptophane4-(2-amino-6-{(1R -1-[4-cloro-2-(3-metil-1H-pirazol-1-il)fenil])-2,2,2-trifluoroetoxi}pirimidin-4-il)-L-fenilalaninainhibidor de la hidroxilasa de triptófanoC 25 H 22 ClF 3 N 6 O 3 1033805-28-5NH 2HCF 3NNOCl N N CH 3HNH 2CO 2 Htregalizumabum #tregalizumabtrégalizumabtregalizumabimmunoglobulin G1-kappa, anti-[Homo sapiens CD4 (T cell surfaceantigen T4/Leu-3, p55)], humanized monoclonal antibody;gamma1 heavy chain (1-454) [humanized VH (Homo sapiensIGHV3-15*06 (77.80%) -(IGHD)-IGHJ5*01) [8.10.15] (1-1<strong>24</strong>) -Homosapiens IGHG1*01 (125-454)], (227-218')-disulfide with kappa lightchain (1'-218') [humanized V-KAPPA (Homo sapiens IGKV4-1*01(80.20%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01(112'-218')]; (233-233":236-236")-bisdisulfide dimerimmunomodulatorimmunoglobuline G1-kappa, anti-[Homo sapiens CD4 (antigène desurface T4/Leu-3 de cellule T, p55)], anticorps monoclonalhumanisé;chaîne lourde gamma1(1-454) [VH humanisé (Homo sapiensIGHV3-15*06 (77.80%) -(IGHD)-IGHJ5*01) [8.10.15] (1-1<strong>24</strong>) -Homosapiens IGHG1*01 (125-454)], (227-218')-disulfure avec la chaînelégère kappa (1'-218') [V-KAPPA humanisé (Homo sapiens IGKV4-1*01 (80.20%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01(112'-218')]; dimère (233-233":236-236")-bisdisulfureimmunomodulateurinmunoglobulina G1-kappa, anti-[CD4 de Homo sapiens (antígenode superficie T4/Leu-3 de célula T, p55)], anticuerpo monoclonalhumanizado;cadena pesada gamma1(1-454) [VH humanizada (Homo sapiensIGHV3-15*06 (77.80%) -(IGHD)-IGHJ5*01) [8.10.15] (1-1<strong>24</strong>) -Homosapiens IGHG1*01 (125-454)], (227-218')-disulfuro con la cadenaligera kappa (1'-218') [V-KAPPA humanizada (Homo sapiens IGKV4-1*01 (80.20%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01(112'-218')]; dimero (233-233":236-236")-bisdisulfuroinmunomodulador395
- Page 1 and 2:
WHO Drug Information Vol. 24, No. 4
- Page 3 and 4:
WHO Drug Information Vol. 24, No. 4
- Page 5 and 6:
WHO Drug Information Vol. 24, No. 4
- Page 7 and 8:
WHO Drug Information Vol. 24, No. 4
- Page 9 and 10:
WHO Drug Information Vol. 24, No. 4
- Page 11 and 12:
WHO Drug Information Vol. 24, No. 4
- Page 13 and 14:
WHO Drug Information Vol. 24, No. 4
- Page 15 and 16:
WHO Drug Information Vol. 24, No. 4
- Page 17 and 18:
WHO Drug Information Vol. 24, No. 4
- Page 19 and 20:
WHO Drug Information Vol. 24, No. 4
- Page 21 and 22:
WHO Drug Information Vol. 24, No. 4
- Page 23 and 24:
WHO Drug Information Vol. 24, No. 4
- Page 25 and 26:
WHO Drug Information Vol. 24, No. 4
- Page 27 and 28:
WHO Drug Information Vol. 24, No. 4
- Page 29 and 30:
WHO Drug Information Vol. 24, No. 4
- Page 31 and 32:
WHO Drug Information Vol. 24, No. 4
- Page 33 and 34:
WHO Drug Information Vol. 24, No. 4
- Page 35 and 36:
WHO Drug Information Vol. 24, No. 4
- Page 37 and 38:
WHO Drug Information Vol. 24, No. 4
- Page 39 and 40:
WHO Drug Information Vol. 24, No. 4
- Page 41 and 42:
WHO Drug Information Vol. 24, No. 4
- Page 43 and 44:
WHO Drug Information Vol. 24, No. 4
- Page 45 and 46:
WHO Drug Information Vol. 24, No. 4
- Page 47 and 48:
WHO Drug Information Vol. 24, No. 4
- Page 49 and 50:
WHO Drug Information Vol. 24, No. 4
- Page 51 and 52:
WHO Drug Information Vol. 24, No. 4
- Page 53 and 54: WHO Drug Information Vol. 24, No. 4
- Page 55 and 56: WHO Drug Information Vol. 24, No. 4
- Page 57 and 58: WHO Drug Information Vol. 24, No. 4
- Page 59 and 60: WHO Drug Information Vol. 24, No. 4
- Page 61 and 62: WHO Drug Information, Vol. 24, No.
- Page 63 and 64: WHO Drug Information, Vol. 24, No.
- Page 65 and 66: WHO Drug Information, Vol. 24, No.
- Page 67 and 68: WHO Drug Information, Vol. 24, No.
- Page 69 and 70: WHO Drug Information, Vol. 24, No.
- Page 71 and 72: WHO Drug Information, Vol. 24, No.
- Page 73 and 74: WHO Drug Information, Vol. 24, No.
- Page 75 and 76: WHO Drug Information, Vol. 24, No.
- Page 77 and 78: WHO Drug Information, Vol. 24, No.
- Page 79 and 80: WHO Drug Information, Vol. 24, No.
- Page 81 and 82: WHO Drug Information, Vol. 24, No.
- Page 83 and 84: WHO Drug Information, Vol. 24, No.
- Page 85 and 86: WHO Drug Information, Vol. 24, No.
- Page 87 and 88: WHO Drug Information, Vol. 24, No.
- Page 89 and 90: WHO Drug Information, Vol. 24, No.
- Page 91 and 92: WHO Drug Information, Vol. 24, No.
- Page 93 and 94: WHO Drug Information, Vol. 24, No.
- Page 95 and 96: WHO Drug Information, Vol. 24, No.
- Page 97 and 98: WHO Drug Information, Vol. 24, No.
- Page 99 and 100: WHO Drug Information, Vol. 24, No.
- Page 101 and 102: WHO Drug Information, Vol. 24, No.
- Page 103: WHO Drug Information, Vol. 24, No.
- Page 107 and 108: WHO Drug Information, Vol. 24, No.
- Page 109 and 110: WHO Drug Information, Vol. 24, No.
- Page 111 and 112: WHO Drug Information, Vol. 24, No.
- Page 113 and 114: WHO Drug Information, Vol. 24, No.
- Page 115 and 116: WHO Drug Information, Vol. 24, No.
- Page 117 and 118: WHO Drug Information, Vol. 24, No.
- Page 119 and 120: WHO Drug Information, Vol. 24, No.
- Page 121 and 122: WHO Drug Information, Vol. 24, No.
- Page 123 and 124: WHO Drug Information, Vol. 24, No.
- Page 125 and 126: WHO Drug Information, Vol. 24, No.
- Page 127 and 128: WHO Drug Information, Vol. 24, No.